Bionet Therapeutics (ROCO:7808) EPS (Basic): NT$-1.39 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7808 Bionet Therapeutics Corp ROCO:7808
12 GF Score
Price NT$31.00
! 2 Warning Signs
View Full Analysis

What is Bionet Therapeutics EPS (Basic)?

Bionet Therapeutics ROCO:7808 12 EPS (Basic) is NT$-1.39 as of Dec. 2025. GuruFocus rates ROCO:7808 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Bionet Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was NT$-0.76. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.39.

Bionet Therapeutics's EPS (Diluted) for the six months ended in Dec. 2025 was NT$-0.76. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.40.

Bionet Therapeutics's EPS without NRI for the six months ended in Dec. 2025 was NT$-0.76. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -1.40.

During the past 3 years, the average EPS without NRI Growth Rate was 40.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Bionet Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 40.70% per year. The lowest was 40.70% per year. And the median was 40.70% per year.

Bionet Therapeutics  (ROCO:7808) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Bionet Therapeutics EPS (Basic) Related Terms

Bionet Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Bionet Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionet Therapeutics EPS (Basic) Chart

Bionet Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-6.67 -2.47 -1.50 -1.39

Bionet Therapeutics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial -0.48 -0.61 -0.89 -0.63 -0.76
ROCO:7808
12GF Score
Bionet Therapeutics Corp ROCO:7808
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionet Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Bionet Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-97.426-0)/70.000
=-1.39

Bionet Therapeutics's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-52.977-0)/70.000
=-0.76

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-1.39 mean?
Bionet Therapeutics (ROCO:7808) has a EPS (Basic) of NT$-1.39 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Bionet Therapeutics and its competitors.
Is Bionet Therapeutics' EPS (Basic) too high?
Bionet Therapeutics' current EPS (Basic) is NT$-1.39. Overall, Bionet Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' EPS (Basic) compare to VRTX and REGN?
Bionet Therapeutics' EPS (Basic) of NT$-1.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Bionet Therapeutics and its competitors. Bionet Therapeutics's current EPS (Basic) is NT$-1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current EPS (Basic) of NT$-1.39. The current EPS (Basic) is NT$-1.39. Bionet Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current EPS (Basic) is NT$-1.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bionet Therapeutics Business Description

Address No.28, Lane. 36 , Xinhu 1st Road, 1st Floor, Neihu District, Taipei, TWN, 11497
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
12GF Score

Get the complete analysis for ROCO:7808

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.00
Price